Shares of Gilead Sciences, Inc. (NASDAQ:GILD) ended Tuesday session in red amid volatile trading. The shares closed down -1.37 points or 1.70% at $79.25 with 13.21 million shares getting traded. Post opening the session at $79.32, the shares hit an intraday low of $78.64 and an intraday high of $79.90 and the price vacillated in this range throughout the day. The company has a market cap of $104.39 billion and the numbers of outstanding shares have been calculated to be 1.32 billion shares.
Gilead Sciences, Inc. (GILD) on September 28, 2016 announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis (VL). As part of this collaboration, Gilead will donate 380,000 vials of AmBisome® (amphotericin B liposome for injection) to meet the needs of WHO to treat VL in key endemic countries, including Bangladesh, Ethiopia, India, Nepal, South Sudan and Sudan.
VL, also known as kala-azar, is the world’s second-deadliest parasitic infectious disease and affects up to 300,000 people annually in resource-limited countries.
“This new collaboration comes at the right time as we gear up to support endemic countries in the Eastern Africa sub-region and South-East Asia to eliminate visceral leishmaniasis as a public health problem by or before 2020,” said Dr. Ren Minghui, WHO Assistant Director-General for HIV/AIDS, Malaria and Neglected Tropical Diseases. “During the past five years, AmBisome, donated by Gilead, allowed many countries in the Region highly endemic for VL to implement WHO’s recommended first line treatment, benefitting thousands of people.”
Shares of Merck & Co., Inc. (NYSE:MRK) ended Tuesday session in green amid volatile trading. The shares closed up +0.42 points or 0.68% at $62.57 with 7.34 million shares getting traded. Post opening the session at $62.31, the shares hit an intraday low of $61.83 and an intraday high of $62.70 and the price vacillated in this range throughout the day. The company has a market cap of $172.85 billion and the numbers of outstanding shares have been calculated to be 2.77 billion shares.
Merck & Co., Inc. (MRK) will hold its third-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 25. During the call, company executives will provide an overview of Merck’s performance for the quarter.
Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx. A replay of the webcast, along with the sales and earnings news release and supplemental financial disclosures, will be available at www.merck.com.
Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 87561377. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 87561377. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call.